AUTL
Autolus Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$1.94
+1.04%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.91
From 52W high−23.62%
Volume1.77M
Market cap$516.36M
P/E (TTM)—
P/S (TTM)4.4x
Div yield—
Key dataSep 18, 2026
Open
$1.91
From 52W high
−23.62%
Volume
1.77M
Market cap
$516.36M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
42.3
MomentumView details →
1D Return
+1.04%
YTD Return
−3.27%
SummaryUpdated Jun 1, 2026
Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in London, United Kingdom. The company specializes in developing engineered T-cell therapies for cancer treatment, with its lead product AUCATZYL receiving FDA approval in November 2024 for treating relapsed or refractory acute lymphoblastic leukemia (ALL) in adults. Autolus has evolved from a pure research and development company to a commercial-stage biotechnology firm with its own manufacturing capabilities and an expanding pipeline of cell therapy candidates targeting both hematological cancers and autoimmune diseases.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration granted regenerative medicine advanced therapy (RMAT) designation to Autolus Therapeutics' obecabtagene autoleucel (obe-cel) for the treatment of systemic lupus erythematosus and lupus nephritis.11d agoAutolus Therapeutics reported preliminary second quarter 2026 net product revenue of approximately $45 million for AUCATZYL and a year-to-date gross margin of approximately 35%.48d ago